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Purpose: Allergic rhinitis (AR) is common among children
with asthma and exacerbates asthma symptoms. To assess the
incremental utilization and cost of asthma-related health
services due to concomitant AR among asthmatic children.
Materials and Methods: Asthma-related claims were extracted
from the Korean National Health Insurance (NHI) claims
database, which covers 97% of the population. Per-capita
utilization and costs of asthma-related services were
determined from the societal perspective. Results: Of 319,714
children (1 - 14 years old) with chronic asthma in 2003,
195,026 had concomitant AR (prevalence 610 per 1,000
asthmatic children). Children with AR had 1.14 times more
outpatient visits, 1.30 times more emergency department (ED)
visits, and 1.49 times more hospitalizations than children
without AR. More children with AR used general hospitals
(7.17%) than children without AR (3.23%). The ratios of unit
pharmaceutical costs per outpatient visit, ED visit, and
admission between children with and without AR were 1.27,
1.20, and 1.14. Total annual expenditure combining direct
health care, transportation, and caregivers' costs, were $273
and $217 for children with and without AR, respectively.
Conclusion: Health service utilization and costs for asthma
were greater for asthmatic children with AR. More frequent
ED visits and admissions among asthmatic children with AR
suggest poorer control and more frequent exacerbations. Higher
unit cost of pharmaceuticals during visits, tendency to receive
asthma care from a higher-level facility, and greater risk of
ED visit or admission all contributed to the additional
economic burden of AR.
Key Words: Asthma, allergic rhinitis, cost of illness, health
care cost
INTRODUCTION
Asthma and allergic rhinitis (AR) are leading
causes of illness in childhood and place a sub-
stantial burden on health care systems worldwide.
The prevalence of childhood asthma varies from
nation to nation. One of the highest prevalences
is observed in the UK, where at least 20% of
children are affected by asthma.
1 Childhood AR,
characterized by mucosal inflammation in response
to allergen exposure, also shows a high pre-
valence rate, with prevalence worldwide of up to
40% in 13- and 14-years-old.
2 AR is common
among patients with asthma and it increases the
risk of acute exacerbation of asthma symptoms.
3-5
Understanding the component health care costs
and health care utilization patterns of asthmatic
children with AR is essential to designing the
most cost-effective strategy to improve patient
outcome and minimize the total cost to society.
In comparison to the wealth of data on the cost
of illness of asthma, there is much less infor-
mation about the cost of illness of AR.
6 The
literature on the incremental economic burden of
AR on patients with asthma is particularly sparse,
especially in children, and previous studies of this
subject relate to US
7,8 or UK populations.
9 As it is
difficult to extrapolate the results to other coun-
tries, which have different health care utilization
patterns and cost structures, studies on Asian
populations are necessary for efficient local
resource allocation.
The main data sources for earlier asthma and
AR cost studies were medical charts, patient
reports, localized administrative data sets, or
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nationally representative (but not nationwide)
primary care databases. Approaches that use
self-reported data to extrapolate economic
consequences from the local to the national level
rely on assumptions that may not be accurate.
Some studies have partially overcome the former
limitation by using administrative data sets. For
example, Grupp-Phelan and colleagues compared
health care utilization and costs of children with
both asthma and AR to those of children with
asthma alone among subjects at a health main-
tenance organization.
8 Although that study
examined a larger population sample than the
studies relying on medical chart reviews or
patient questionnaires, it was based on only 1
HMO program and was not representative of the
country as a whole. Thomas and colleagues used
a nationally representative primary care database
from the UK, but this did not include the entire
national population.
9
Centralized insurance claims databases in
countries like Korea that have a national health
care system show health service utilization of the
entire population for specific medical conditions
over extended periods of time.
10 The objective of
this study, therefore, was to use the NHI claims
database of Korea to assess the incremental health
service use and costs of concomitant AR in
treating childhood asthma.
MATERIALS AND METHODS
Data sources
We used the electronic administrative claims
records of the Korean NHI database as a major
data source to track health care services provided
to asthmatic children during 2003. The NHI claims
database includes all medical and prescription
drug claims for covered services provided to
about 97% of the population. All asthma-related
claims were extracted for children with asthma
with and without AR. An asthma-related claim
was defined as a primary, secondary, or tertiary
diagnosis of asthma and an expenditure greater
than 0 dollar for a prescribed anti-asthma
medicine. We aggregated each patient's claims to
produce patient-level information on the total
annual asthma-related health service utilization
and cost. For data not included in the NHI
database, we used the Korean National Health
and Nutrition Survey (NHNS) and various
publicly available sources specified in detail
below.
Study cohort
Children 1 to 14 years of age were defined as
having asthma if they had at least two medical
claims with a primary, secondary, or tertiary
diagnosis of asthma, indicated by International
Classification of Disease (ICD)-9 code 493.X and a
prescription for an anti-asthma medicine in 2003.
Anti-asthma medicines included beta-agonists,
methylxanthines (theophylline), mast cell stabilizers
(cromolyn, nedocromil), anti-leukotrienes, anti-
cholinergics, and corticosteroids. A complete list
was created on the specific drugs (oral, injected,
and inhaled) that were available and covered by
the NHI for the treatment of childhood asthma.
An admission claim with a record of a prescrip-
tion for an anti-asthma medicine and a procedural
code for arterial blood gas analysis or nebulizer
treatment of the lower airways, which are routine
procedures for patients hospitalized for asthma,
was classified as an asthma case even if it was not
accompanied by a primary, secondary, or tertiary
diagnosis of asthma. Similarly, we considered
outpatient visits without a diagnosis of asthma as
asthma cases if they included a prescription for an
inhaled corticosteroid or a leukotriene modifier,
which are used only to treat asthma in Korea.
Children with asthma claims with a co-diagnosis
of chronic obstructive pulmonary disease, cystic
fibrosis, bronchitis, bronchiolitis, pneumonia, or
emphysema were excluded.
Among all children identified with asthma,
those with at least one medical claim during 2003
with a primary, secondary, or tertiary diagnosis of
AR(ICD-9 code 477.X) or prescriptions of oral 2nd
generation antihistamines (acrivastine, cetirizine,
ebastine, fexofenadine, loratadine, and mizolastine)
or intranasal glucosteroids (beclomethasone,
budesonide, fluticasone, mometasone, and triam-
cinolone) were defined as having concomitant AR.
The remaining children were defined as having
asthma without AR.Effect of Allergic Rhinitis on Health Care Cost
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To determine AR-related prescription medi-
cines, we conducted a literature review and con-
sulted a group of pediatricians.
9,11 The AR-related
prescription medicines include 1st-, 2nd-, and
3rd-generation antihistamines, intranasal steroids,
oral and topical decongestants, and leukotriene
receptor antagonists. Not all of these medicines
were suitable to be used to identify AR cases since
they are not specific to AR or not used to treat
pediatric patients. For example, 1st-generation
antihistamines, and oral and topical decongestants
are frequently used to treat common colds. The
3rd-generation antihistamines are rarely used to
treat children under 15 year in Korea. Because
leukotriene receptor antagonists are used to treat
both asthma and AR, it is not easy to determine
whether the use of this medicine is for AR. On the
other hand, the pediatrician panel members
agreed that the 2nd-generation antihistamines and
intranasal steroids are mostly prescribed to treat
pediatric AR but rarely prescribed to treat
common colds. A complete list was created for the
specific drugs of the 2nd-generation antihis-
tamines and intranasal steroids that were avail-
able and covered by the NHI for the treatment of
childhood AR.
Outcome variables
The outcomes of interest were health service
utilization and cost. Patient encounters were
classified into non-urgent outpatient visits,
urgent ED visits, and hospital admissions. A
claim was categorized as an ED visit if it in-
cluded an emergency care charge, was submitted
from an ED, or occurred during the night,
weekend, or holiday. Total asthma-related costs
were assessed from the societal perspective and
computed as the sum of the cost for direct
health service, transportation for visits to health
care providers, and caregivers' time spent on
outpatient visits or inpatient stays of asthmatic
children.
Direct health service costs were divided into
insured and uninsured costs. Insured costs were
given in the NHI data. Uninsured costs for each
claim were computed from the proportion of
uninsured costs among total health care costs,
previously estimated on the basis of hospital
charge records.
12 The reported proportion of
uninsured costs was 31.1% for the 15 most
frequent conditions requiring outpatient visits and
19.9% for admission with asthma or chronic
pulmonary disease. We measured pharmaceutical
costs as "anti-asthma pharmaceutical costs" and
"all pharmaceutical costs". Anti-asthma pharma-
ceutical costs only included prescribed anti-
asthma medicines only and all pharmaceutical
costs were the sum of anti-asthma medicines and
all other medicines prescribed during an asthma-
related visit or admission.
Transportation costs for visits to health care
institutions for outpatient or inpatient care were
estimated by multiplying the average round-trip
transportation cost by the total number of asthma-
related visits and admissions in the country per
year. The average round-trip cost for different
types of institutions based on the 2001 Korean
NHNS has been estimated at $2.60 (using a 2001
exchange rate of 1,000 Korean Won for 1 US
dollar).
13 The average round-trip cost in 2001 was
converted for 2003 using the ratio of the price
index for transportation in 2003 (109.1) to that in
2001 (104.2).
For working mothers, the cost of the loss of
time due to physician visits or admission was
measured as forgone wages, following the human
capital approach. If mothers did not participate in
the labor market, we used the "replacement cost
approach"
14 which quantifies the cost of replacing
the homemaker's time spent in the home with
commercially available services (e.g. cleaning,
child care). The average daily time cost for a
Korean woman 30 - 49 years of age was calculated
from their labor market participation rate,
15
average daily wage,
16 and market price for the
daily wage of a domestic worker.
17 We assumed
that the primary caregivers of asthmatic children
were their mothers and that the age range of
mothers of children 1 to 14 years of age was 30
to 49 years. Finally, the total time cost for asthma-
related visits or admissions was estimated as the
product of the total number of visits or admis-
sions, average time spent for a visit or inpatient
stay, and average hourly or daily time cost for a
Korean woman 30 to 49 years of age. The average
time spent for an outpatient visit to different types
of institutions (20.3 minutes) was obtained fromHye-Young Kang, et al.
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the 2001 NHNS.
18
Data analysis
We compared per-capita utilization and costs of
asthma-related services for asthmatic children (i.e.
children identified as receiving anti-asthma
treatments) to AR (i.e. children identified as
receiving anti-rhinitis treatments) and asthmatic
children without AR. Per-capita utilization and
costs were expressed as visits, hospitalizations,
inpatient days, or dollars spent per child per year.
Cost and utilization ratios were computed as
per-capita cost (or utilization) for asthmatic
children with AR divided by per-capita cost (or
utilization) for asthmatic children without AR.
Mean treatment costs for an outpatient visit, ED
visit, and hospitalization were also compared.
Statistical significance testing in nationwide
administrative datasets usually has no practical
meaning because the patient groups are so large
that all between-group differences are significant.
Therefore, tests of statistical significance were not
performed.
RESULTS
Of 319,714 children identified as having chronic
asthma in 2003, 195,026 had concomitant AR,
yielding a prevalence of 61.0% or 610 per 1000
asthmatic children. The prevalence of AR among
asthmatic children increased with age. School-age
children (6 - 14 years of age) with asthma showed
the highest prevalence of AR (61.4%), followed by
children 2 - 5 years (61.3%), and children 1 to < 2
years (58.0%; Table 1).
Table 2 shows the number and percentage of
children with at least one recorded use of an
asthma-related service during the study year by
service category and institution type. A greater
percentage of children with AR had at least one
asthma-related admission (0.96% versus 0.64%)
and ED visit (0.79% versus 0.69%) than those
without AR. There were more stays or visits in
hospitals, general hospitals, and tertiary care
hospitals by children with AR (3.89%, 7.17%, and
3.04%, respectively) than by children without AR
(2.16%, 3.23%, and 1.52%). Children with asthma
alone (96.53%) tended to visit clinics more often
than did children with concomitant AR (93.64%).
Per-capita utilization of asthma-related health
services was greater among asthmatic children
with AR. On average, children with AR had 1.14
times more outpatient visits than those without
AR. For ED visits and hospital admissions,
per-capita utilization by children with AR was
1.30 and 1.49 times greater, respectively, than by
those without AR (Table 3). Asthmatic children
with AR had 29% greater total asthma-related
Table 1. Proportion of Asthmatic Children with or without Allergic Rhinitis by Sex and Age
All asthmatic children
n (%)*
With AR
n (%)
Without AR
n (%)
Total (n) 319,714 195,026 (61.0) 124,688 (39.0)
Gender
Boys 183,935 (57.5) 113,228 (61.6) 70,707 (38.4)
Girls 135,779 (42.5) 81,798 (60.2) 53,981 (39.8)
Age (yrs)
1 to < 2 35,247 (11.0) 20,443 (58.0) 14,804 (42.0)
2 to 5 195,414 (61.1) 119,865 (61.3) 75,549 (38.7)
6 to 14 89,053 (27.9) 54,718 (61.4) 34,335 (38.6)
AR, allergic rhinitis.
*Column percent.
Row percent.Effect of Allergic Rhinitis on Health Care Cost
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insured costs than children without AR: $160.60
versus $124.80 per child per year. The average
annual per-capita costs of all pharmaceuticals and
anti-asthma medicines prescribed during asthma
visits or admissions were 46% and 61%, greater
for children with AR than for children without AR
respectively. For both children with and without
AR, outpatient visits were the greatest single-
Table 2. Distribution of Asthmatic Children by Type of Health Service and Institution
No. of children using asthma-related services (%)
Total
(n = 319,714)
Children with AR
(n = 195,026)
Children without AR
(n = 124,688)
Type of service
Non-urgent outpatient visit 319,577 (99.96) 194,957 (99.96) 124,620 (99.95)
Urgent ED visit 2,398 (0.75) 1,543 (0.79) 855 (0.69)
Hospital admission 2,674 (0.84) 1,877 (0.96) 797 (0.64)
Type of institution
Tertiary care hospital 7,815 (2.44) 5,920 (3.04) 1,895 (1.52)
General hospital 18,004 (5.63) 13,977 (7.17) 4,027 (3.23)
Hospital 10,284 (3.22) 7,590 (3.89) 2,694 (2.16)
Clinic 302,978 (94.77) 182,617 (93.64) 120,361 (96.53)
ED, emergency department; AR, allergic rhinitis.
Table 3. Annual Per-Capita Use and Insured Costs of Asthma-Related Health Services by Asthmatic Children with or
without Allergic Rhinitis in 2003
Type of service
Asthmatic children
Ratio
With AR Without AR
Per-capita utilization
Non-urgent outpatient visit 8.221 7.203 1.14
ED visit 0.012 0.009 1.30
Admission 0.010 0.007 1.49
Inpatient days 0.053 0.034 1.54
Per-capita insured costs (in 2003, US $)
Non-urgent outpatient visit 81.4 70.5 1.15
ED visit 0.5 0.43 1.16
Admission 3.5 2.2 1.57
All pharmaceuticals* 75.1 51.6 1.46
Anti-asthma pharmaceuticals 27.7 17.2 1.61
Total 160.6 124.8 1.29
AR, allergic rhinitis; ED, emergency department.
*"All pharmaceuticals" were anti-asthma medicines and all other medicines prescribed during an asthma-related visit or admission.
Ratios were computed as the per-capita utilization for asthmatic children with AR divided by the per-capita utilization for asthmatic
children without AR.Hye-Young Kang, et al.
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category expenditure (50.7% and 56.5%, respec-
tively), followed by prescribed medicines (46.8%
and 41.4%) (Table 3).
Mean treatment costs per outpatient visit, ED
visit, and admission were similar for children
with and without AR. However, expenditures for
pharmaceuticals during a visit or admission were
greater for children with AR than for those
without AR. The ratios between the two groups
(with AR:without AR) of mean pharmaceutical
costs during an outpatient visit, ED visit, and
admission were 1.27, 1.20, and 1.14, respectively
(Table 4).
Total expenditure, combining direct health
service, transportation, and caregivers' time costs,
for asthmatic children with AR was 1.26 times
greater than total expenditure for children with
asthma alone. Direct health service costs accounted
for 85.0% and 83.7% of total expenditure for asth-
matic children with AR and without AR respec-
tively (Table 5).
DISCUSSION
This study adds to our understanding about the
impact of comorbid AR among asthmatic children
on the use of health care services and costs related
to asthma. Asthmatic children used 14 - 54% more
health care services if they had concomitant AR.
The tendency to seek asthma care from a higher-
level institution such as a general hospital or
tertiary care hospital was more pronounced
among asthmatic children with AR. The ratio of
per-capita costs for asthmatic children with and
without AR varied depending on the type of
service with the greatest ratios seen for pharma-
ceuticals. For anti-asthma pharmaceuticals, annual
per-capita spending for insured services was
about 61% greater for asthmatic children with AR
than for those without AR.
The incremental effect of comorbid AR on
medical care costs of treating asthma has con-
sistently been observed in previous studies. For
example, analysis of medical charge data for a
random sample of 1,412 asthmatic children
younger than 15 years old from the asthma
incidence and prevalence cohorts of Rochester,
Minnesota, showed that the total annual medical
care charges for children with comorbid AR were
almost twice those for children with asthma
alone.
7 Another US-based study of enrollees in a
staff model Health Maintenance Organization
reported that mean total health care costs for
asthmatic children with multiple visits for upper
respiratory comorbidities such as AR, otitis media,
or sinusitis, were 1.7 times higher than for children
with asthma alone.
8 Finally, according to multi-
variable analyses from a recent population-based
historical cohort study conducted in the UK,
Table 4. Mean Unit Costs of Asthma-Related Health Services for Asthmatic Children with or without Allergic Rhinitis
in 2003
Type of service
Asthmatic children
Ratio
With AR (US $) Without AR (US $)
Outpatient visit 9.9 9.8 1.01
ED visit 42.7 47.9 0.89
Admission 342.2 323.6 1.06
Pharmaceuticals*
During outpatient visit 9.0 7.1 1.27
During ED visit 6.9 5.7 1.20
During admission 88.2 77.2 1.14
AR, allergic rhinitis; ED, emergency department.
Treatment costs only include insured costs.
*All pharmaceuticals, i.e., anti-asthma medicines and all other medicines prescribed during an asthma-related visit or admission.Effect of Allergic Rhinitis on Health Care Cost
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comorbid AR was an independent predictor of a
higher risk of asthma-related hospitalization and
greater costs for all categories of asthma medica-
tions (p < 0.05).
9
Interestingly, the unit treatment cost (average
treatment cost per visit or admission) was similar
for the two groups. In contrast, the unit pharma-
ceutical cost during a visit or admission was 27%
to 14% greater among asthmatic children with AR.
This suggests that pharmaceuticals are an
important source of the additional health care ex-
penditures due to AR among asthmatic children.
Thus, effective control of AR symptoms could
contribute to a reduction in the use and costs of
pharmaceuticals. The incremental indirect cost,
expressed in terms of the opportunity cost for the
caregiver's time loss, was about 18% higher for
children with AR than for those without AR. This
suggests that the caregiver's time cost is also an
important component of AR-related costs.
The 1-year prevalence of treated AR in the
Korean asthmatic population of 1 to 14-year-old
children in 2003 was estimated as 61.0%. Although
methods of identifying asthmatic children with
concomitant AR varied, we can compare our
results with those of previous studies. A
population-based study conducted in the US
estimated that 38.5% of asthmatic children
younger than 15 year had concomitant AR.
7 In a
retrospective cohort study conducted in UK, about
19.7% of children 6 to 15 year old had both
asthma and AR.
9 The prevalence in all of these
Table 5. Annual Per-Capita Costs (in 2003 US $) of Asthma-Related Health Services for Asthmatic Children with
or without AR
Type of service
Direct costs (I)
Transportation
cost
(II)
Caregiver's
time cost
(III)
Total cost
(I)+(II)+(III)
Insured costs
Uninsured
costs Insurer
payment
Patient
co-pay
Children with AR
Outpatient visits (1) 53.3 28.1 36.8 22.3 16.1 156.6
ED visits (2) 0.24 0.26 0.23 0.03 - 0.8
Admissions (3) 2.8 0.71 0.88 0.03 2.4 6.9
All pharmaceuticals (4)* 52.7 22.5 33.73 - - 108.9
Anti-asthma pharmaceuticals 19.4 8.3 12.45 - - 40.1
Total (1)-(4) 109.0 51.6 71.6 22.4 18.5 273.1
Children without AR
Outpatient visits (1) 47.4 23.1 31.8 19.6 14.1 136.0
ED visits (2) 0.21 0.23 0.20 0.02 - 0.7
Admissions (3) 1.8 0.45 0.56 0.02 1.6 4.4
All pharmaceuticals (4)* 36.9 15.4 23.19 - - 75.6
Anti-asthma pharmaceuticals 12.0 5.1 10.81 - - 28.0
Total (1)-(4) 86.4 39.2 55.8 19.6 15.7 216.6
Ratio 1.28 1.14 1.18 1.26
AR, allergic rhinitis; ED, emergency department.
*"All pharmaceutical costs" were the summed costs of anti-asthma medicines and all other medicines prescribed during an
asthma-related visit or admission.
Mean costs for asthmatic children with AR divided by mean costs for asthmatic children without AR.Hye-Young Kang, et al.
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studies is relatively low. The reason may lie in
underreporting/under-diagnosis/undertreatment
of AR in administrative databases used in pre-
vious studies. A recent post-hoc analysis of a well-
characterized clinical trial population suggests
that 61% of children aged 6 - 14 years with asthma
also have physician-diagnosed and self-reported
AR.
19
In this study, the presence of asthma was
defined by both a diagnosis of asthma and
treatment with an anti-asthma medicine. It is not
unusual in Korea for providers to up-code a
patient's diagnosis to a disease that is more severe
than their actual condition in order to justify
treatment and increase reimbursement. The use of
an anti-asthma medication was included in
addition to a diagnosis of asthma to minimize the
misclassification of up-coded asthma as true
asthma cases.
Unlike asthma cases, we determined the
presence of concomitant AR by either a diagnosis
or treatment with an anti-AR medicine. The
prevalence of AR among asthmatic children was
only 22.5% if AR cases were identified by both
diagnosis and the use of an anti-AR medicine.
Considering the tendency of under-diagnosis or
under-treatment of AR,
9,11 we thought that clas-
sifying AR cases by either a diagnosis or AR-
related medicine was appropriate to minimize
missing AR subjects.
Pharmaceutical costs were measured as "anti-
asthma pharmaceutical costs" and "all pharma-
ceutical costs". In clinical practice, patients are
treated with antibiotics, medicines for indigestion,
and other medicines in addition to anti-asthma
medicines. The cost of all pharmaceuticals, in-
cluding anti-asthma medicines and other related
medicines, reflects the true cost of pharmaceu-
ticals prescribed for childhood asthma.
Several limitations to this research should be
addressed in future studies. First, given the nature
of insurance claims data, we were unable to
identify asthmatic children who did not receive
treatment. This could have led to overestimation
of the per-capita cost of asthma. Similarly, because
the NHI does not cover over-the-counter drugs,
these costs did not appear in the administrative
data and were not represented in the study results.
Second, a prevalence-based approach was taken to
quantify the economic burden of childhood
asthma, where both incident and prevalent cases
were considered over a one-year period.
20 Per-
capita health service utilization and costs were
calculated by dividing the total national utiliza-
tion or costs by the number of incident and
prevalent asthma cases identified in 2003. If only
prevalent asthma cases were considered (i.e.,
children with pre-existing asthma before 2003), we
would underestimate the true costs of the
combined population of incident and prevalent
cases. In addition, per-capita utilization and costs
were calculated on a per-calendar year rather than
a per-person year basis. For example, a patient
who was diagnosed with asthma for the first time
in July 2003 and had 3 outpatient visits in the
remaining part of the year would be counted as
having 3 visits per calendar year although the
number of visits per person-year would be 6 (3
visits/0.5 year).
Third, if patients with or without AR in this
study were identified by medical chart review, it
would be possible to have more confidence in
identifying true AR cases. However, since our
dataset was national medical claims data and
claims data do not have detailed clinical informa-
tion, we relied on diagnosis code and the use of
AR-related prescription medicines in identifying
AR cases. Based on the literature review
11,12 and
consultation with the pediatrician panel, we
considered that the diagnosis code and AR-related
prescription medicines would be the best possible
information that can be used from claims data to
identify AR cases. However, this is apparently a
limitation of the study due to the nature of claims
data. A future study, evaluating the validity of
diagnosis of AR in NHI claims data would be
helpful to assess the accuracy of AR cases
identified on the basis of diagnosis of AR.
In conclusion, asthmatic children had substan-
tially higher utilization and costs for treating
asthma if they had concomitant AR. Asthma-
related ED visits and admissions were about 1.30
to 1.49 times more frequent among asthmatic
children with AR than those without, suggesting
poorer control and more frequent exacerbations
among asthmatic children with AR. Higher unit
costs of pharmaceuticals during a visit or admis-
sion, a greater tendency to receive asthma careEffect of Allergic Rhinitis on Health Care Cost
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from higher level health care institutions, more
frequent asthma-related visits, and a greater risk
of ED visits or admission all contributed to the
added economic burden resulting from AR.
Compared to prior studies of the incremental cost
of AR, the present study has the advantage of a
centralized national claims database representing
the entire medically insured population of the
country. In addition, it is the first nationwide
study addressing the issue of health care costs
related to concomitant asthma and AR in patients
in an East Asian country. These findings, there-
fore, uniquely contribute in their potential to
enhance the understanding of the effect of
concomitant AR on the use and costs of health
services for childhood asthma.
ACKNOWLEDGEMENT
The authors thank Katherine Myung-Lim Song,
M.S., Young Joo Kang, M.S., and Yoon-Nam Kim,
M.S. of PHARMAX Research & Consulting, Inc.,
Seoul, South Korea for their assistance in data
analysis and management.
REFERENCES
1. Chung F, Barnes N, Allen M, Angus R, Corris P, Knox
A, et al. Assessing the burden of respiratory disease in
the UK. Respir Med 2002;96:963-75.
2. Strachan D, Sibbald B, Weiland S, Aït-Khaled N,
Anabwani G, Anderson HR, et al. Worldwide varia-
tions in prevalence of symptoms of allergic rhinocon-
junctivitis in children: the International Study of
Asthma and Allergies in Childhood (ISAAC). Pediatr
Allergy Immunol 1997;8:161-76.
3. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria
Workshop Group; World Health Organization. Allergic
rhinitis and its impact on asthma. J Allergy Clin Immu-
nol 2001;108 (5 Suppl):S147-334.
4. Schoenwetter WF, Dupclay L Jr, Appajosyula S,
Botteman MF, Pashos CL. Economic impact and
quality-sof-life burden of allergic rhinitis. Curr Med
Res Opin 2004;20:305-17.
5. Blaiss MS. Cognitive, social, and economic costs of
allergic rhinitis. Allergy Asthma Proc 2000;21:7-13.
6. Weiss KB, Sullivan SD. The health economics of asthma
and rhinitis. I. Assessing the economic impact. J Allergy
Clin Immunol 2001;107:3-8.
7. Yawn BP, Yunginger JW, Wollan PC, Reed CE,
Silverstein MD, Harris AG. Allergic rhinitis in
Rochester, Minnesota residents with asthma: frequency
and impact on health care charges. J Allergy Clin
Immunol 1999;103:54-9.
8. Grupp-Phelan J, Lozano P, Fishman P. Health care
utilization and cost in children with asthma and
selected comorbidities. J Asthma 2001;38:363-73.
9. Thomas M, Kocevar VS, Zhang Q, Yin DD, Price D.
Asthma-related health care resource use among
asthmatic children with and without concomitant
allergic rhinitis. Pediatrics 2005;115:129-34.
10. Birnbaum HG, Cremieux PY, Greenberg PE, LeLorier
J, Ostrander JA, Venditti L. Using healthcare claims
data for outcomes research and pharmacoeconomic
analyses. Pharmacoeconomics 1999;16:1-8.
11. Crown WH, Olufade A, Smith MW, Nathan R. Seasonal
versus perennial allergic rhinitis: drug and medical
resource use patterns. Value Health 2003;6:448-56.
12. Jung HJ. Estimating non-covered medical cost. Health
Insurance Forum 2002;1:73-97 (Korean).
13. Yang BM. Developing criteria for estimating standard
costs used in economic evaluation studies for medicines
(technical report: Korean). Seoul, Korea: Health
Insurance Review Agency; 2004. p.149.
14. Drummond MF, O'Brien BJ, Stoddart GL, Torrance
GW. Chapter 7. Cost-benefit analysis. In: Methods for
the economic evaluation of health care programmes.
Oxford: Oxford University Press; 2005. p.216.
15. Korea National Statistics Office. Age- and gender-specific
participation rate to labor market 2002. Available form:
URL: http://www.kosis.kr.
16. Korean Ministry of Labor. Statistics for wage structure.
2002. Available form: URL: http://www.laborstat.molab.
go.kr.
17. Korea YWCA. Personal talk with Korea YWCA
administrator 2004.
18. Yang BM. Developing criteria for estimating standard
costs used in economic evaluation studies for medicines
(technical report: Korean). Seoul, Korea: Health
Insurance Review Agency; 2004. p.152-3.
19. Garcia-Garcia ML, Wahn U, Gilles L, Swern A, Tozzi
CA, Polos P. Montelukast, compared with fluticasone,
for control of asthma among 6- to 14-year-old patients
with mild asthma: The MOSAIC study. Pediatrics
2005;116:360-9.
20. Kang HY, Kim HJ, Park TK, Jee SH, Nam CM, Park
HW. Economic burden of smoking in Korea. Tob
Control 2003;12:37-44.